Surgical Castration as an Alternative for Hormone-Refractory Prostate Cancer
Author Information
Author(s): Masayoshi Zaitsu, Mariko Yamanoi, Koji Mikami, Yuta Takeshima, Naohiko Okamoto, Sadao Imao, Akiko Tonooka, Takumi Takeuchi
Primary Institution: Kanto Rosai Hospital
Hypothesis
Can surgical castration be an effective alternative for patients with hormone-refractory metastatic prostate cancer?
Conclusion
Surgical castration can be a viable option for hormone-refractory prostate cancer patients due to various endocrinological, oncological, and economic reasons.
Supporting Evidence
- Surgical castration led to a 74% reduction in PSA levels in one patient.
- 44.9% of medically castrated patients had testosterone levels below the sensitivity threshold.
- 98.9% of patients achieved testosterone levels below 0.5 ng/mL after medical castration.
Takeaway
Some men with advanced prostate cancer that doesn't respond to hormone treatments might still benefit from surgery to remove their testicles.
Methodology
Twelve hormone-refractory prostate cancer patients underwent surgical castration, and serum testosterone levels were measured before and after the procedure.
Limitations
The study is based on a small sample size and lacks controlled trials.
Participant Demographics
Patients had multiple bone metastases and were aged between 45 and 90 years.
Statistical Information
P-Value
0.039
Statistical Significance
p=0.039
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website